Analyst Activity – Credit Suisse Group Raises Its Price Target On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $195.00

ME Staff
-
0

Analyst Ratings For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Today, Credit Suisse Group raised its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $195.00 per share.

There are 3 hold ratings, 21 buy ratings on the stock.

The current consensus rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is Buy (Score: 2.88) with a consensus target price of $130.70 per share, a potential 1.11% downside.

Some recent analyst ratings include

  • 7/19/2017-JMP Securities Reiterated Rating of Outperform.
  • 7/19/2017-Raymond James Financial, Inc. Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 7/19/2017-Jefferies Group LLC Reiterated Rating of Buy.
  • 7/19/2017-HC Wainwright Reiterated Rating of Hold.
  • 7/19/2017-Janney Montgomery Scott Upgrade from a “Neutral ” rating to a ” Buy” rating.

Recent Insider Trading Activity For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has insider ownership of 1.80% and institutional ownership of 94.08%.

  • On 7/3/2017 Jeffrey Chodakewitz, CMO, sold 3,438 with an average share price of $127.80 per share and the total transaction amounting to $439,376.40. View SEC Filing
  • On 6/21/2017 Jeffrey Chodakewitz, CMO, sold 5,157 with an average share price of $132.87 per share and the total transaction amounting to $685,210.59. View SEC Filing
  • On 6/21/2017 Paul M Silva, SVP, sold 2,577 with an average share price of $133.36 per share and the total transaction amounting to $343,668.72. View SEC Filing
  • On 6/5/2017 David Altshuler, EVP, sold 7,500 with an average share price of $130.00 per share and the total transaction amounting to $975,000.00. View SEC Filing
  • On 6/2/2017 Jeffrey M Leiden, CEO, sold 147,101 with an average share price of $129.50 per share and the total transaction amounting to $19,049,579.50. View SEC Filing
  • On 6/2/2017 Sangeeta N Bhatia, Director, sold 1,176 with an average share price of $128.44 per share and the total transaction amounting to $151,045.44. View SEC Filing
  • On 6/2/2017 Stuart A Arbuckle, EVP, sold 70,969 with an average share price of $128.06 per share and the total transaction amounting to $9,088,290.14. View SEC Filing

Recent Trading Activity for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Shares of Vertex Pharmaceuticals Incorporated closed the previous trading session at 163.45 up +31.29 23.67% with 3,311,555 shares trading hands.